Alkermes (ALKS) has scored big gains so far in 2013, but it continues to hang in a possible buying range. The Ireland-headquartered biotech is a turnaround story, just like Regeneron (REGN), a biotech featured in this column for Thursday's IBD. As noted in a Sept. 18 New America article, Alkermes has made an impressive comeback from its unprofitable years thanks to a 2011 merger with Elan Drug Technologies, the drug formulation and manufacturing